128 related articles for article (PubMed ID: 38206144)
1. Extension Phase of a Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang JV; Fabi SG; Robinson DM; Bajaj S; Geronemus RG; Bell M; Robison T; Widgerow AD
J Drugs Dermatol; 2024 Jan; 23(1):1266-1270. PubMed ID: 38206144
[TBL] [Abstract][Full Text] [Related]
2. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J; Fabi S; Robinson D; Bajaj S; Geronemus R; Bell M; Widgerow A
J Drugs Dermatol; 2023 Apr; 22(4):333-338. PubMed ID: 37026875
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
Kaufman BP; Alexis AF
J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
[TBL] [Abstract][Full Text] [Related]
4. Topical Treatments for Melasma and Post-inflammatory Hyperpigmentation.
Sadick N; Pannu S; Abidi Z; Arruda S
J Drugs Dermatol; 2023 Nov; 22(11):1118-1123. PubMed ID: 37943277
[TBL] [Abstract][Full Text] [Related]
5. Comparing the Efficacy and Tolerability of Moderate to Severe Hyperpigmentation and Skin Unevenness.
Callender VD; Orlinsky D; Simmons-O'Brien E; Nwade NC; Rhodes T; Byrd AS
J Drugs Dermatol; 2024 Jan; 23(1):1260-1265. PubMed ID: 38206158
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging.
Fabi SG; Goldman MP
J Drugs Dermatol; 2013 Mar; 12(3):S32-7. PubMed ID: 23545931
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a novel multimodality hydroquinone-free skin brightener over six months.
Bruce S
J Drugs Dermatol; 2013 Mar; 12(3):S27-31. PubMed ID: 23545930
[TBL] [Abstract][Full Text] [Related]
8. In Vitro and In Vivo Efficacy and Tolerability of a Non-Hydroquinone, Multi-Action Skin Tone Correcting Cream.
Grimes PE; McDaniel DH; Wortzman M; Nelson D
J Drugs Dermatol; 2019 Jul; 18(7):642-648. PubMed ID: 31329402
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability on melasma of a topical cosmetic product acting on melanocytes, fibroblasts and endothelial cells: a randomized comparative trial against 4% hydroquinone.
Bronzina E; Clement A; Marie B; Fook Chong KT; Faure P; Passeron T
J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):897-903. PubMed ID: 31858658
[TBL] [Abstract][Full Text] [Related]
10. Combination of In-Office Chemical Peels With a Topical Comprehensive Pigmentation Control Product in Skin of Color Subjects With Facial Hyperpigmentation.
Downie J; Schneider K; Goberdhan L; Makino ET; Mehta RC
J Drugs Dermatol; 2017 Apr; 16(4):301-306. PubMed ID: 28403262
[TBL] [Abstract][Full Text] [Related]
11. A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation.
Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Wu DC; Goldman MP
J Drugs Dermatol; 2017 Nov; 16(11):1127-1132. PubMed ID: 29141061
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women.
Lima PB; Dias JAF; Cassiano D; Esposito ACC; Bagatin E; Miot LDB; Miot HA
Int J Dermatol; 2020 Dec; 59(12):1531-1536. PubMed ID: 32864760
[TBL] [Abstract][Full Text] [Related]
13. A randomized, controlled, split-face, double-blind comparison of a multimodality pigment-correcting serum containing lotus sprout extract versus hydroquinone for moderate to severe facial hyperpigmentation, including melasma, in a diverse population.
Huang P; Acevedo SF; Cheng T; Mehta RC; Makino ET
JAAD Int; 2024 Jun; 15():206-219. PubMed ID: 38707930
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of 755-nm picosecond alexandrite laser with topical tranexamic acid versus laser monotherapy for melasma and facial rejuvenation: a multicenter, randomized, double-blinded, split-face study in Chinese patients.
Li Y; Yao C; Zhang H; Li L; Song Y
Lasers Med Sci; 2022 Sep; 37(7):2879-2887. PubMed ID: 35501519
[TBL] [Abstract][Full Text] [Related]
15. Combined use of two formulations containing diacetyl boldine, TGF-β1 biomimetic oligopeptide-68 with other hypopigmenting/exfoliating agents and sunscreen provides effective and convenient treatment for facial melasma. Either is equal to or is better than 4% hydroquinone on normal skin.
Pratchyapurit WO
J Cosmet Dermatol; 2016 Jun; 15(2):131-44. PubMed ID: 26833454
[TBL] [Abstract][Full Text] [Related]
16. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation.
Grimes PE
Cutis; 2004 Dec; 74(6):362-8. PubMed ID: 15663072
[TBL] [Abstract][Full Text] [Related]
17. Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation.
Desai S; Ayres E; Bak H; Manco M; Lynch S; Raab S; Du A; Green D; Skobowiat C; Wangari-Talbot J; Zheng Q
J Drugs Dermatol; 2019 May; 18(5):454-459. PubMed ID: 31141852
[TBL] [Abstract][Full Text] [Related]
18. Pigmentation control in pregnancy-induced melasma: Clinical assessment of a non-hydroquinone, non-retinol pigment-correcting serum.
Makino ET; Jiang LI; Stephens TJ; Mikati M; Mehta RC
J Cosmet Dermatol; 2022 Nov; 21(11):5739-5746. PubMed ID: 35708506
[TBL] [Abstract][Full Text] [Related]
19. The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial.
Adalatkhah H; Sadeghi-Bazargani H
Drug Des Devel Ther; 2015; 9():4219-25. PubMed ID: 26345129
[TBL] [Abstract][Full Text] [Related]
20. The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types.
Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Fabi SG
Dermatol Surg; 2018 Oct; 44(10):1304-1310. PubMed ID: 29659405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
